Amgen olpasiran may fill critical treatment gap in lowering Lp(a): GlobalData
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
This study showed that patients taking 75mg of Olpasiran previously every 12 weeks presented a 40–50% reduction in LP(a)
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
This indigenously developed enhanced care technology is designed to continuously monitor and detect early signs of deterioration in a patient's condition
This is a strategic acquisition for Cipla South Africa to unlock the future growth opportunities in the South African market
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
This approval has come from the company's finished dosage form manufacturing facility
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
Health Assurance is a unique healthcare model that combines health insurance with preventive healthcare with a focus on keeping people healthy while providing sick care for them when needed
Sets price band at ?695 to ?735 per Equity Share
Subscribe To Our Newsletter & Stay Updated